Insider Trading Alert - MTOR, ARRY, SJM, RNR And AMZN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 3, 2013, 126 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $225.86 to $7,867,379.00.

Highlighted Stocks Traded by Insiders:

Meritor (MTOR) - FREE Research Report

Baker Vernon G Ii who is Senior VP and General Counsel at Meritor sold 4,848 shares at $7.75 on Dec. 3, 2013. Following this transaction, the Senior VP and General Counsel owned 260,428 shares meaning that the stake was reduced by 1.83% with the 4,848-share transaction.

Craig Jeffrey A who is Sr. VP/Pres. Comm.Truck/Indus at Meritor sold 8,729 shares at $7.73 on Dec. 3, 2013. Following this transaction, the Sr. VP/Pres. Comm.Truck/Indus owned 355,441 shares meaning that the stake was reduced by 2.4% with the 8,729-share transaction.

Novak Barbara Griffin who is VP and Corp Sec at Meritor sold 1,746 shares at $7.74 on Dec. 3, 2013. Following this transaction, the VP and Corp Sec owned 46,017 shares meaning that the stake was reduced by 3.66% with the 1,746-share transaction.

Nowlan Kevin who is Senior VP CFO at Meritor sold 1,091 shares at $7.75 on Dec. 3, 2013. Following this transaction, the Senior VP CFO owned 49,281 shares meaning that the stake was reduced by 2.17% with the 1,091-share transaction.

The shares most recently traded at $7.86, up $0.11, or 1.41% since the insider transaction. Historical insider transactions for Meritor go as follows:

  • 4-Week # shares bought: 17,119
  • 12-Week # shares bought: 17,119
  • 24-Week # shares bought: 20,169

The average volume for Meritor has been 1.4 million shares per day over the past 30 days. Meritor has a market cap of $758.1 million and is part of the consumer goods sector and automotive industry. Shares are up 64.48% year-to-date as of the close of trading on Tuesday.

Meritor, Inc. designs, develops, manufactures, sells, markets, distributes, services, and supports integrated systems, modules, and components to original equipment manufacturers (OEMs) and the aftermarket for the commercial vehicle, transportation, and industrial sectors. Currently there are 3 analysts that rate Meritor a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTOR - FREE

TheStreet Quant Ratings rates Meritor as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and poor profit margins. Get the full Meritor Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Array BioPharma (ARRY) - FREE Research Report

Moore John R who is VP, General Counsel at Array BioPharma sold 11,666 shares at $5.79 on Dec. 3, 2013. Following this transaction, the VP, General Counsel owned 20 shares meaning that the stake was reduced by 99.83% with the 11,666-share transaction.

The shares most recently traded at $5.95, up $0.16, or 2.69% since the insider transaction. Historical insider transactions for Array BioPharma go as follows:

  • 4-Week # shares sold: 200
  • 12-Week # shares sold: 200
  • 24-Week # shares sold: 4,959

The average volume for Array BioPharma has been 2.0 million shares per day over the past 30 days. Array BioPharma has a market cap of $717.4 million and is part of the health care sector and drugs industry. Shares are up 55.91% year-to-date as of the close of trading on Tuesday.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Currently there are 7 analysts that rate Array BioPharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARRY - FREE

TheStreet Quant Ratings rates Array BioPharma as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and feeble growth in its earnings per share. Get the full Array BioPharma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

J.M. Smucker (SJM) - FREE Research Report

Denman John W who is Vice President, Controller at J.M. Smucker sold 200 shares at $104.50 on Dec. 3, 2013. Following this transaction, the Vice President, Controller owned 18,480 shares meaning that the stake was reduced by 1.07% with the 200-share transaction.

The shares most recently traded at $105.06, up $0.56, or 0.53% since the insider transaction. Historical insider transactions for J.M. Smucker go as follows:

  • 4-Week # shares sold: 200
  • 12-Week # shares sold: 700
  • 24-Week # shares sold: 22,131

The average volume for J.M. Smucker has been 527,800 shares per day over the past 30 days. J.M. Smucker has a market cap of $11.0 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 21.12% year-to-date as of the close of trading on Tuesday.

The J. M. Smucker Company engages in manufacturing and marketing branded food products worldwide. The company operates through three segments: U.S. Retail Coffee; U.S. Retail Consumer Foods; and International, Foodservice, and Natural Foods. The stock currently has a dividend yield of 2.22%. The company has a P/E ratio of 19.7. Currently there are 7 analysts that rate J.M. Smucker a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SJM - FREE

TheStreet Quant Ratings rates J.M. Smucker as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, increase in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full J.M. Smucker Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RenaissanceRe Holdings (RNR) - FREE Research Report

Todd Rider Fonner who is Svp & Cio at RenaissanceRe Holdings sold 2,000 shares at $94.50 on Dec. 3, 2013. Following this transaction, the Svp & Cio owned 64,829 shares meaning that the stake was reduced by 2.99% with the 2,000-share transaction.

The shares most recently traded at $94.30, down $0.20, or 0.21% since the insider transaction. Historical insider transactions for RenaissanceRe Holdings go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 37,000
  • 24-Week # shares sold: 69,000

The average volume for RenaissanceRe Holdings has been 364,800 shares per day over the past 30 days. RenaissanceRe Holdings has a market cap of $4.2 billion and is part of the financial sector and insurance industry. Shares are up 16.15% year-to-date as of the close of trading on Tuesday.

RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The stock currently has a dividend yield of 1.19%. The company has a P/E ratio of 10.2. Currently there are 5 analysts that rate RenaissanceRe Holdings a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNR - FREE

TheStreet Quant Ratings rates RenaissanceRe Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full RenaissanceRe Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amazon.com (AMZN) - FREE Research Report

Alberg Tom A who is Director at Amazon.com sold 3,780 shares at $396.81 on Dec. 3, 2013. Following this transaction, the Director owned 23,795 shares meaning that the stake was reduced by 13.71% with the 3,780-share transaction.

The shares most recently traded at $387.87, down $8.94, or 2.31% since the insider transaction. Historical insider transactions for Amazon.com go as follows:

  • 4-Week # shares sold: 1.0 million
  • 12-Week # shares sold: 1.0 million
  • 24-Week # shares sold: 2.1 million

The average volume for Amazon.com has been 2.8 million shares per day over the past 30 days. Amazon.com has a market cap of $179.6 billion and is part of the services sector and retail industry. Shares are up 56.38% year-to-date as of the close of trading on Tuesday.

Amazon.com, Inc. operates as an online retailer in North America and internationally. The company operates in two segments, North America and International. The company has a P/E ratio of 1401.1. Currently there are 23 analysts that rate Amazon.com a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMZN - FREE

TheStreet Quant Ratings rates Amazon.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Amazon.com Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff